Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pentostatin

Drug Profile

Pentostatin

Alternative Names: 2'-Deoxycoformycin; CI 825; Coforin; DCF; Deoxycoformycin; Nipent; Nipentin; NSC 218321; Oncopent; PD 81565; YK 176

Latest Information Update: 06 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA); Pfizer
  • Developer Hospira; National Cancer Institute (USA); Pfizer
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Adenosine deaminase inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Chronic lymphocytic leukaemia; Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hairy cell leukaemia
  • No development reported Cutaneous T-cell lymphoma
  • Discontinued Graft-versus-host disease; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 Sep 2015 Hospira has been acquired by Pfizer
  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top